Berenberg set EUR 102 target for Redcare Pharmacy stock
Published on 10/27/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- On October 7, 2026, Berenberg set a EUR 102.00 price target for Redcare Pharmacy stock.
- Redcare Pharmacy will publish its third-quarter 2026 interim statement on October 29, 2026.
- Redcare Pharmacy stock costs EUR 78.25 at Lang & Schwarz on October 27, 2026 at 6:08 p.m. CEST, 1.62 percent above the Xetra close of October 27, 2026.
- Full-year 2026 total revenue growth guidance stands at 16.00 to 18.00 percent.
On October 7, 2026, Berenberg maintained its Buy rating and set a EUR 102.00 price target for Redcare Pharmacy, according to Markets Insider. Redcare Pharmacy stock was trading at EUR 78.25 at Lang & Schwarz on October 27, 2026 at 6:08 p.m. CEST, up 1.62 percent versus the Xetra close of October 27, 2026 at EUR 77.00.
What does the target imply?
The Berenberg target lies 30.35 percent above the Lang & Schwarz price. The analyst action gives investors a quantified benchmark ahead of Redcare Pharmacy's next operating update, while the stock remains 23.06 percent below its 52-week high of EUR 82.55.
German prescription growth leads
Redcare Pharmacy raised its full-year 2026 total revenue growth guidance to 16.00 to 18.00 percent from 15.00 to 17.00 percent on September 28, 2026. The company's German prescription revenue guidance increased to EUR 730.00 million to EUR 760.00 million from EUR 680.00 million to EUR 720.00 million, according to Redcare Pharmacy. Preliminary German prescription revenue rose 56.00 percent year over year in the third quarter of 2026, while the adjusted EBITDA margin stayed between 2.50 and 3.00 percent in the full-year outlook.
Price position after hours
The primary Xetra quote was EUR 77.95 on October 27, 2026 at 6:38 p.m. CEST, while the 52-week range stood at EUR 30.20 to EUR 82.55. The market capitalization was EUR 1.6 billion and trading volume was 55,674 shares on the same date.
Redcare Pharmacy's price-to-earnings ratio was negative 37.30 on October 27, 2026. The stock's 52-week high is EUR 82.55, placing the Lang & Schwarz price 5.21 percent below that level.
Dates and operating checks
Redcare Pharmacy will publish its interim statement for the third quarter of 2026 and hold its quarterly conference call on October 29, 2026. The company also lists its Annual Report 2026 for March 4, 2027, according to its September 28, 2026 release.
The coming report will put the raised prescription revenue range alongside the confirmed adjusted EBITDA margin. That comparison matters because the guidance combines 45.00 to 51.00 percent German prescription growth with a 2.50 to 3.00 percent adjusted EBITDA margin.
Market position in context
Redcare Pharmacy operates a digital pharmacy business across Europe and has been listed on the Frankfurt regulated market since 2016. Its business covers prescription and over-the-counter medicines, healthcare products and related consumer categories.
Stock level and next report
Redcare Pharmacy stock was trading at EUR 78.25 at Lang & Schwarz on October 27, 2026 at 6:08 p.m. CEST, 1.62 percent above the Xetra close of October 27, 2026 at EUR 77.00.
The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy market data
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 27, 2026, 6:08 p.m. CEST): EUR 78.25
- Change versus Xetra close: plus 1.62 percent
- Xetra close (October 27, 2026): EUR 77.00
- Market capitalization: EUR 1.6 billion (as of October 27, 2026)
- 52-week range: EUR 30.20-EUR 82.55 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report AEX.
